7 October 2026
QPCT and QPCTL are enzymes that catalyze the conversion of N-terminal glutamine into pyroglutamate, a post-translational modification that can influence the stability and biological activity of different proteins. QPCT is a secreted enzyme associated with the modification and stabilization of amyloid beta peptides, while the Golgi-resident enzyme QPCTL acts on substrates including chemokines and CD47.
The pyroglutamate modification of CD47 is required for its interaction with SIRPα, a signaling axis associated with the “don’t eat me” signal of tumor cells. QPCT and QPCTL biology has therefore attracted considerable research interest across a broad range of biological processes and disease-relevant pathways. To support the scientific community in investigating these enzymes and their biological functions, Boehringer Ingelheim is making BI-3614 available through opnMe.
BI-3614 is a potent and highly selective orthosteric inhibitor with approximately equipotent activity against QPCT and QPCTL. It has been developed as an in vitro tool compound suitable for cellular investigations. BI-3614 combines single-digit nanomolar potency against both human enzymes with strong cellular activity. The compound is also active in cellular assays using Raji and A549 cells, where it inhibits the interaction between CD47 and SIRPα.
Researchers can use BI-3614 to study QPCT and QPCTL function, substrate modification, and the consequences of inhibiting QPCT/L-dependent pathways in cellular systems. To support rigorous experimental design and interpretation, BI-3614 is provided together with the structurally related negative control BI-9692.
Access the full BI-3614 profile on opnMe and order the active molecule and its negative control free of charge to support your research.
No registration required
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About BI-3614:
BI-3614 is a potent and highly selective orthosteric dual inhibitor of QPCT and QPCTL. The compound combines single-digit nanomolar potency with strong cellular activity and is cross-reactive with the corresponding mouse enzymes. BI-3614 displays a highly selective profile in broad safety and kinase screening panels and possesses physicochemical properties suitable for in vitro investigations. These characteristics make it a valuable tool for studying QPCT/L biology and pyroglutamate-dependent pathways in cellular systems. A structurally related negative control compound, BI-9692, is also available.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. As part of our “Molecules to Order” pillar, we share well-characterized tool compounds free of charge with no IP strings attached. With “opn2EXPERTS”, we enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our opn2TALENTS PostDoc grants provide an opportunity for high-caliber talents to pitch their scientific approaches for well-defined research questions to conduct their research at one of our discovery research sites.